ANTABIO

Antabio is a private biopharmaceutical company headquartered in Labège (France) developing novel and highly differentiated antibacterial treatments for WHO critical priority pathogens with a particular focus on life-threatening respiratory infections. The company’s portfolio is composed of three drug development programs that target high unmet needs such as drug-resistant nosocomial pneumonia (“SBLI” program), complicated urinary tract infections (“MBLI” program) and chronic lung infections in cystic fibrosis patients (“PEi” program). Antabio’s activities are funded through equity investment from European investors and VC firms such as Omnes, BNP Paribas Développement, Turenne, Sham Innovation, IRDI Soridec, IXO PE and Galia Gestion. The company has also received non-dilutive funding from the Region, CARB-X and the Wellcome Trust.

The areas of interest to Antabio, either directly or through its active participation to the BEAM Alliance, are: the Pharmaceutical Strategy, SME Strategy, Horizon Europe Partnerships - Innovative Health Initiative (IHI) Partnership, European Partnership for One Health Antimicrobial Resistance and European Partnership on Innovative SMEs - European Innovation Council (EIC), InvestEU, AMR Joint Action, Innovative Medicines Initiative and the EU4Health Programme.

http://antabio.com

1

0.25

No lobbyists with EP accreditations

Marc Lemonnier, CEO

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

Companies & groups